Neuphoria Therapeutics

NEUPPre-clinical

San Diego, United StatesFounded 2020neuphoriatx.com

Neuphoria Therapeutics is dedicated to addressing the significant unmet medical needs in psychiatry and neurology by advancing a pipeline of innovative CNS therapeutics. Its lead candidate, NPH-101, is a novel rapid-acting antidepressant in Phase 2 development for major depressive disorder. The company's strategy is built on a deep understanding of neurocircuitry and a platform designed to identify compounds with superior efficacy and tolerability compared to existing treatments.

Market Cap

$24.9M

Founded

2020

Employees

11-50

Focus

Biotech

AI Company Overview

Technology Platform

Proprietary discovery platform integrating computational modeling and behavioral assays to identify novel, rapid-acting neuroactive compounds with improved safety profiles for CNS disorders.

Opportunities

The significant unmet need in depression and anxiety creates a large addressable market for effective new therapies.

Success with its lead candidate could enable expansion into adjacent CNS indications, such as PTSD or bipolar depression.

Positive clinical data may attract strategic partnership or acquisition interest from larger pharmaceutical companies.

Risk Factors

High risk of clinical trial failure inherent to CNS drug development.

Dependence on raising additional capital to fund operations through key milestones.

Intense competition from both established pharmaceuticals and novel therapeutic modalities entering the market.

Competitive Landscape

Faces competition from large pharma (e.g., J&J's Spravato) and biotech peers (e.g., Axsome's Auvelity) in the depression space. Differentiation is sought through novel mechanisms aimed at providing rapid oral antidepressants without the safety or logistical limitations of current rapid-acting therapies.